MINNEAPOLIS & REHOVOT, Israel--(BUSINESS WIRE)--Stratasys Ltd. (Nasdaq:SSYS), a global leader of 3D printing and additive manufacturing solutions today introduced the highest precision wax 3D printers available to the dental industry.
The Stratasys CrownWorx and FrameWorx 3D Printers allow dental laboratories to produce wax-ups for crowns, bridges and denture frameworks. The machines will be unveiled May 17 at the LMT Lab Day West Show in booth number B8.
Stratasys CrownWorx and FrameWorx 3D Printers use wax deposition modeling technology, a jetting technology that is designed to enable consistent quality and a reliable process. The machines produce superior-fitting wax-ups for crown, bridge, coping and denture frameworks via an automated method that can fit easily into a lab’s established workflow, enhancing production capacity.
Stratasys CrownWorx and FrameWorx 3D Printers use wax-like materials that produce smooth surface finishes and minimize post-processing. The materials burn-out with no residue, material shrinkage, cracking or expansion to allow precision casting and reduce costs previously incurred when finishing gold and other precious metals.
Based on resolution, the CrownWorx 3D Printer is best-in-class for creating crown, bridge, and coping wax-ups. CrownWorx uses WDM Technology to jet micro-drops of TrueCast material that builds dental wax-ups, layer-by-layer.
The FrameWorx 3D Printer uses WDM Technology to jet micro-drops of TrueCast material onto the build tray to create a denture wax-up layer-by-layer. TrueSupport material is quickly sprayed around the casting material to form a support structure. This enhancement increases production speed for partial denture wax-ups because they require more support material than crowns and bridges. After printing, TrueSupport is dissolved, leaving behind smooth and detailed wax-ups.
“These wax 3D printers and new materials are an ideal fit for small labs interested in upgrading dental casting technology,” says Stratasys Director of Global Dental, Avi Cohen. “We believe dental labs adopting these 3D printers will benefit from the automated and digitized workflows, enabling them to cut costs while producing more restorations. These systems complement our broad system portfolio, which includes large dental 3D printers.”
TrueCast and TrueSupport
TrueCast is a firm but flexible material that mimics real wax and allows labs to 3D print any dental wax-up with extreme accuracy. It is 100 percent castable for any alloy. TrueSupport is a true wax-blend material that is automatically generated to protect a wax-up during printing. It has a low melting point that produces delicate restorations and is easily removed from each wax-up, after production.
More information about CrownWorx, FrameWorx, TrueCast and TrueSupport is available at www.StratasysDental.com.
Editors: For images, video and other resources, visit the Stratasys newsroom.
Stratasys Ltd. (Nasdaq:SSYS), headquartered in Minneapolis, Minnesota and Rehovot, Israel, is a leading global provider of 3D printing and additive manufacturing solutions. The company's patented FDM®, PolyJet TM, and WDM™ 3D Printing technologies produce prototypes and manufactured goods directly from 3D CAD files or other 3D content. Systems include 3D printers for idea development, prototyping and direct digital manufacturing. Stratasys subsidiaries include MakerBot and Solidscape, and the company operates the RedEye digital-manufacturing service. Stratasys has more than 1900 employees, holds over 550 granted or pending additive manufacturing patents globally, and has received more than 25 awards for its technology and leadership. Online at: www.stratasys.com or http://blog.stratasys.com
Stratasys is a registered trademark, and WDM, WDM Technology, CrownWorx, FrameWorx, TrueCast and TrueSupport are trademarks of Stratasys Ltd and its affiliates or subsidiaries.
Cautionary Statement Regarding Forward-Looking Statements
Certain information included or incorporated by reference in this press may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements may include, but are not limited to, statements relating to the company’s objectives, plans and strategies, statements regarding the expected performance and impact of our products, statements that contain projections of results of operations or of financial condition (including, with respect to the MakerBot acquisition) and all statements (other than statements of historical facts) that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. The company has based these forward-looking statements on assumptions and assessments made by its management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things: the company’s ability to efficiently and successfully integrate the operations of Stratasys, Inc. and Objet Ltd. after their merger as well as MakerBot after its acquisition and to successfully put in place and execute an effective post-merger integration plans; the overall global economic environment; the impact of competition and new technologies; general market, political and economic conditions in the countries in which the company operates; projected capital expenditures and liquidity; changes in the company’s strategy; government regulations and approvals; changes in customers’ budgeting priorities; litigation and regulatory proceedings; and those factors referred to under “Risk Factors”, “Information on the Company”, “Operating and Financial Review and Prospects”, and generally in the company’s annual report on Form 20-F for the year ended December 31, 2013 filed with the U.S. Securities and Exchange Commission and in other reports that the company has filed with the SEC. Readers are urged to carefully review and consider the various disclosures made in the company’s SEC reports, which are designed to advise interested parties of the risks and factors that may affect its business, financial condition, results of operations and prospects. Any forward-looking statements in this press release are made as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Attention Editors, if you publish reader-contact information, please use:
- USA +1-877-489-9449
- Europe/Middle East/Africa +49-7229-7772-0
- Asia Pacific +852 39448888